> Markdown version of https://theevidenceledger.com/c/remdesivir-mortality for AI agents. You are welcome here, and welcome back anytime. What an agent can do: https://theevidenceledger.com/agents .

# Remdesivir - The Evidence Ledger

[The Evidence Ledger](/)

[← The Evidence Ledger](/)

### [Remdesivir](/c/remdesivir-mortality)

MechanismESTABLISHEDOutcomeB

Claimed

Remdesivir reduces death in hospitalized COVID-19 patients.

What holds up

Remdesivir is a nucleoside analogue inhibiting the viral RNA-dependent RNA polymerase, with reproduced in-vitro activity against SARS-CoV-2 and animal-model efficacy; the antiviral mechanism is textbook, though its link to mortality weakens late in disease when immune-mediated damage dominates. ACTT-1 (n=1062) showed day-29 mortality of 11.4% vs 15.2% (hazard ratio 0.73, 95% CI 0.52-1.03), crossing 1.0. The WHO Solidarity final analysis found overall mortality RR 0.91 (p=0.12) but a significant reduction in patients not ventilated at baseline (RR 0.86, p=0.02) and in the composite of death or progression to ventilation (RR 0.84, p=0.001). The Amstutz individual-patient meta-analysis (10,480 patients, 8 RCTs) found significant 28-day mortality reduction in patients on no or low-flow oxygen (adjusted OR 0.80, high-certainty evidence). WHO reversed its November 2020 recommendation against remdesivir in April 2022, and FDA approved it in October 2020 for hospitalized patients.

What it does not show

No large RCT showed a statistically significant overall mortality benefit, but a consistent signal appears across prospective trials in non-ventilated patients, confirmed by individual-patient data. No trial demonstrated a significant overall mortality benefit in the full hospitalized population; ACTT-1's mortality result was a non-significant secondary endpoint and Solidarity's overall result was null. In already-ventilated patients Solidarity found no benefit (RR 1.13, p=0.32), and DisCoVeRy stopped its remdesivir arm for futility with no day-28 death difference. The claim as a blanket statement overstates the trials; the honest reading is a probable mortality benefit confined to patients not yet ventilated.

Evidence for

Beigel JH et al., N Engl J Med 2020;383:1813-1826, PMID 32445440, DOI 10.1056/NEJMoa2007764, WHO Solidarity Trial Consortium, Lancet 2022;399(10339):1941-1953, PMID 35512728, DOI 10.1016/S0140-6736(22)00519-0, Amstutz A et al., Lancet Respir Med 2023;11(5):453-464, PMID 36828006, DOI 10.1016/S2213-2600(22)00528-8, US FDA press release, "FDA Approves First Treatment for COVID-19," Oct 22, 2020, fda.gov, WHO Therapeutics and COVID-19 living guideline (Siemieniuk et al., BMJ 2020;370:m3379; updated Nov 2020, Apr 2022, Sep 2022)

Sources

VERIFIED Beigel JH et al., N Engl J Med 2020;383:1813-1826, PMID 32445440, DOI 10.1056/NEJMoa2007764. VERIFIED WHO Solidarity Trial Consortium, Lancet 2022;399(10339):1941-1953, PMID 35512728, DOI 10.1016/S0140-6736(22)00519-0. VERIFIED Amstutz A et al., Lancet Respir Med 2023;11(5):453-464, PMID 36828006, DOI 10.1016/S2213-2600(22)00528-8. VERIFIED US FDA press release, "FDA Approves First Treatment for COVID-19," Oct 22, 2020, fda.gov. PENDING Ader F et al., Lancet Infect Dis 2022;22:209-221, PMID 34534511, DOI 10.1016/S1473-3099(21)00485-0. PENDING WHO Solidarity Trial Consortium (interim), N Engl J Med 2021;384:497-511, DOI 10.1056/NEJMoa2023184. PENDING WHO Therapeutics and COVID-19 living guideline (Siemieniuk et al., BMJ 2020;370:m3379; updated Nov 2020, Apr 2022, Sep 2022).

## Grade history (append-only)

Every grade change is kept, never overwritten, so the current grade and every prior one stay visible.

Mechanism gradeJustificationGraded byStateGraded at

ESTABLISHEDRemdesivir is a nucleoside analogue inhibiting the viral RNA-dependent RNA polymerase, with reproduced in-vitro activity against SARS-CoV-2 and animal-model efficacy; the antiviral mechanism is textbook, though its link to mortality weakens late in disease when immune-mediated damage dominates. ACTT-1 (n=1062) showed day-29 mortality of 11.4% vs 15.2% (hazard ratio 0.73, 95% CI 0.52-1.03), crossing 1.0. The WHO Solidarity final analysis found overall mortality RR 0.91 (p=0.12) but a significant reduction in patients not ventilated at baseline (RR 0.86, p=0.02) and in the composite of death or progression to ventilation (RR 0.84, p=0.001). The Amstutz individual-patient meta-analysis (10,480 patients, 8 RCTs) found significant 28-day mortality reduction in patients on no or low-flow oxygen (adjusted OR 0.80, high-certainty evidence). WHO reversed its November 2020 recommendation against remdesivir in April 2022, and FDA approved it in October 2020 for hospitalized patients.admindisplayed2026-10-08T23:52:30.414Z

Outcome gradeJustificationGraded byStateGraded at

BNo large RCT showed a statistically significant overall mortality benefit, but a consistent signal appears across prospective trials in non-ventilated patients, confirmed by individual-patient data. No trial demonstrated a significant overall mortality benefit in the full hospitalized population; ACTT-1's mortality result was a non-significant secondary endpoint and Solidarity's overall result was null. In already-ventilated patients Solidarity found no benefit (RR 1.13, p=0.32), and DisCoVeRy stopped its remdesivir arm for futility with no day-28 death difference. The claim as a blanket statement overstates the trials; the honest reading is a probable mortality benefit confined to patients not yet ventilated.admindisplayed2026-10-08T23:52:30.415Z

[Submit evidence for or against this claim](/submit?claim=remdesivir-mortality)

Want to hear what's next for The Evidence Ledger?

Email me about it

Add my name and number (optional)

No spam. One email when there is something to show, and you can reply to a real person.